Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


34th International Conference on Nano Materials and Nanotechnology

Edinburgh, Scotland

Nongyue He

Nongyue He


Title: Aptamers selected for breast cancer diagnostics and therapy


Biography: Nongyue He


Aptamers are single-stranded DNAs or RNAs specifically binds to various targets, which show great potential in the early diagnostics and therapy of cancer, due to their superiority over antibodies. Molecular subtyping of breast cancer remains a challenge in clinic medicine, which plays a crucial role in the treatment. In this study, four ssDNA aptamers against MCF-7 breast cancer cells were developed by Cell-SELEX for differentiating breast cancer subtypes. Among all these aptamers, aptamer MF3 showed better specificity than other apatmers as well as favorable binding affinity towards MCF-7 cells with a Kd value of 82.25 ± 25.14 nM. Aptamer MF3 can not only successfully distinguish MCF-7 breast cancer cells from MDA-MB-231, SK-BR-3 breast cancer cells and MCF-10A human normal mammary epithelial cells, but also can differentiate MCF-7 cells from other cancer cells or normal cells, such as A549 lung cancer cells, HepG2 hepatocellular carcinoma cells, L02 normal hepatic cells, HeLa cells, A375 melanoma cells, SGC-7901 gastric carcinoma cells and GES-1 gastric epithelial cells. Moreover, the results of in vivo fluorescence imaging of tumor-bearing mice indicated that aptamer MF3 can distinguish the xenografts of MCF-7 cells tumor-bearing mice from that of MDA-MB-231 and SK-BR-3 cells tumor-bearing mice in vivo. Finally, the bio-distribution of aptamer MF3 also suggested its potential application for the targeted therapy of breast cancer. Collectively, all these results demonstrated aptamer MF3 a promising highly-effective theranostic tool for the personalized medicine of breast cancer